Reviewer’s report

Title: Efficacy and safety of Mycophenolate Mofetil treatment on IgA nephropathy: a systematic review

Version: 1 Date: 4 August 2014

Reviewer: Nan Chen

Reviewer’s report:

The system review about Efficacy and safety of Mycophenolate Mofetil treatment on IgA nephropathy had provide us some useful information. These results are interesting and give the nephrologists some construction view. Also, there are some limitation about the review as following.

- Major Compulsory Revisions

1. Were the patients in the MMF groups, CTX group or LEF group treated with steroid meantime? Are the patients in the placebo group not given with steroid? What are the treatment regiment in the placebo group?

- Minor Essential Revisions

1. This review included 7 studies involved 273 patients, 148 of which were in the MMF groups and 125 in the control groups (48 in the placebo group, 31 in the steroid group, 26 in the CTX group, and 20 in the LEF group). The quality are quite different among these 7 studies. The race is different. The selected control groups are different.

2. In the sub-group analysis in comparing MMF with CTX or LEF, the number of the studies is too few, just about 1-2 studies. Same as in the sub-group analysis in the short period or long period.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No